Corium International Inc. (CORI) Expected to Post Q1 2017 Earnings of ($0.40) Per Share
Corium International Inc. (NASDAQ:CORI) – Investment analysts at Leerink Swann issued their Q1 2017 earnings per share (EPS) estimates for shares of Corium International in a research report issued to clients and investors on Tuesday. Leerink Swann analyst J. Gerberry anticipates that the firm will post earnings per share of ($0.40) for the quarter. Leerink Swann currently has a “Buy” rating and a $16.00 price target on the stock. Leerink Swann also issued estimates for Corium International’s Q2 2017 earnings at ($0.41) EPS, Q4 2017 earnings at ($0.31) EPS, FY2017 earnings at ($1.44) EPS, FY2018 earnings at ($1.68) EPS and FY2019 earnings at ($1.78) EPS.
Other equities analysts have also issued reports about the stock. FBR & Co set a $18.00 target price on shares of Corium International and gave the company a “buy” rating in a report on Friday, August 5th. Zacks Investment Research lowered shares of Corium International from a “hold” rating to a “sell” rating in a report on Tuesday, October 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 target price on shares of Corium International in a report on Monday, September 26th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $12.25.
Corium International (NASDAQ:CORI) remained flat at $4.70 during midday trading on Thursday. 128,830 shares of the company’s stock were exchanged. Corium International has a one year low of $3.14 and a one year high of $9.93. The company has a 50 day moving average of $5.04 and a 200 day moving average of $4.71. The company’s market capitalization is $104.37 million.
Large investors have recently added to or reduced their stakes in the stock. RTW Investments LLC boosted its stake in Corium International by 22.6% in the third quarter. RTW Investments LLC now owns 1,045,747 shares of the biopharmaceutical company’s stock worth $5,888,000 after buying an additional 192,786 shares in the last quarter. Paloma Partners Management Co bought a new stake in Corium International during the second quarter worth about $152,000. Finally, Opaleye Management Inc. boosted its stake in Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock worth $1,390,000 after buying an additional 5,000 shares in the last quarter. 88.35% of the stock is currently owned by hedge funds and other institutional investors.
About Corium International
Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.
Receive News & Stock Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related stocks with our FREE daily email newsletter.